ImmunityBio Inc. Stock
€7.14
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for ImmunityBio
sharewise wants to provide you with the best news and tools for ImmunityBio, so we directly link to the best financial data sources.
Financials
News
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies
Oncology is the largest therapeutic area in the biopharma industry, in terms of sales. The rapid rise in recent years of drugs to treat diabetes and manage weight loss might disrupt the traditional
Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700%
ImmunityBio (NASDAQ:IBRX), a developer of cancer and infectious-disease immunotherapies, closed Monday at $9.83, up 12.99%. The stock moved higher after earnings highlighted 700% ANKTIVA revenue
Why ImmunityBio Stock Is Soaring Again Today
Shares of cancer immunotherapy specialist ImmunityBio (NASDAQ: IBRX) are up 16% as of noon ET on Monday after the company reported fourth-quarter earnings. The company's leading immunotherapy (and
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer
ImmunityBio (NASDAQ:IBRX), which develops immunotherapies and vaccines for cancers and infectious diseases, closed Wednesday at $8.54, up 41.86%. The stock jumped after the European Commission
Why ImmunityBio Stock Is Soaring Today
Wednesday's trading session is proving to be a thrilling one for ImmunityBio (NASDAQ: IBRX) shareholders. As of 1:50 p.m. ET today the biopharma stock is up an incredible 33.1%. The reason
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer
ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month
ImmunityBio (NASDAQ:IBRX), an immunity-focused biotech, closed Friday’s session at $6.45, down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month.
Trading
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
ImmunityBio (NASDAQ:IBRX), which develops immunotherapies for cancers and infectious diseases, closed Wednesday at $6.92, up 6.79%. The stock moved higher as short-sellers considered what to do
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer
ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year
ImmunityBio (NASDAQ:IBRX), cancer and infectious disease immunotherapy developer, closed Friday at $5.52, up 39.75% for the session. The stock climbed after Premarket updates highlighted explosive
Why ImmunityBio Stock Is Skyrocketing Again Today
Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (NASDAQ: IBRX), spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%
ImmunityBio (NASDAQ:IBRX), a cancer and infectious-disease drug developer, closed Thursday at $3.95, up 30.79% for the session. The stock jumped after preliminary 2025 results highlighted roughly
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know
Heights Capital Management recently established a new position in ImmunityBio (NASDAQ:IBRX), buying 6,565,709 shares valued at approximately $16.15 million.
Heights Capital Management disclosed a